Advertisement

Topics

Arno Therapeutics, Inc. Company Profile

09:36 EST 21st November 2018 | BioPortfolio

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. In addition to AR-67, Arno's lead clinical compound is AR-12, a potentially first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces autophagy and the endoplasmic reticulum stress pathway, which is currently enrolling patients in a Phase I clinical study. Arno is also developing AR-42, an orally available targeted pan-HDAC inhibitor that received FDA acceptance of its IND in 2009.


News Articles [732 Associated News Articles listed on BioPortfolio]

ASHG honors Jan M. Friedman with Arno Motulsky-Barton Childs Award

(American Society of Human Genetics) The American Society of Human Genetics (ASHG) has named Jan M. Friedman, M.D., Ph.D., as the 2018 recipient of the Arno Motulsky-Barton Childs Award for Excellence...

Digitisation as a driver of product development

To discover more about digitisation s role in Korsch AG s overall scheme, Dr Kevin Robinson caught up with Stephan Mies, Chairman, and Arno Rathmann, Director of Automation

Arno Therapeutics Inc ARNI Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryArno Therapeutics Inc Arno is a clinical stage biopharmaceutical company that develops products for the treatment of cancer, infectious diseases and other life threatening diseases. The company...

Arno Therapeutics Inc ARNI Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryArno Therapeutics Inc Arno is a clinical stage biopharmaceutical company that develops products for the treatment of cancer, infectious diseases and other life threatening diseases. The company...

£20bn promised to NHS but questions over where money will come from

Theresa May finally attempted to tackle the elephant in the room for the UK government, well, the one other than progression of Brexit discussions, by pledging that the NHS would receive a funding boo...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, which will be headquartered in Japan and known as MAGiQ Therapeutics Inc. R...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

PubMed Articles [466 Associated PubMed Articles listed on BioPortfolio]

A 'pink salmon' returns to the River Arno.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [162 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1272 Associated Companies listed on BioPortfolio]

Arno Therapeutics, Inc.

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. In addition to AR-...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Arno Therapeutics, Inc." on BioPortfolio

We have published hundreds of Arno Therapeutics, Inc. news stories on BioPortfolio along with dozens of Arno Therapeutics, Inc. Clinical Trials and PubMed Articles about Arno Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Arno Therapeutics, Inc. Companies in our database. You can also find out about relevant Arno Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Stress
Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Discovered by Walter Cannon in 1932, it is the release of h...


Corporate Database Quicklinks



Searches Linking to this Company Record